AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
5,183.00
+21.00 (+0.41%)
As of 8:49AM BST. Market open.
Stock chart is not supported by your current browser
Previous close5,162.00
Open5,157.00
Bid5,183.00 x 6100
Ask5,184.00 x 13000
Day's range5,157.00 - 5,184.00
52-week range3,996.00 - 5,520.00
Volume77,772
Avg. volume2,558,113
Market cap65.61B
Beta0.63
PE ratio (TTM)17.00
EPS (TTM)N/A
Earnings dateN/A
Forward Dividend & Yield2.79 (4.51%)
Ex-dividend date2017-08-10
1y target estN/A
  • EQS Group3 hours ago

    ADC Therapeutics Announces Closing of $200 Million Private Financing to Fund Two Lead Programs Through Registrational Trials

    EQS Group-News: ADC Therapeutics SA / Key word(s): Financing23.10.2017 / 06:55

  • Fool.co.uk2 days ago

    Why I see more upside ahead for AstraZeneca plc

    I believe that AstraZeneca plc's (LON: AZN) growth is only just getting started and there's still plenty of potential for investors.

  • Cancer Treatment Update: Second Gene Therapy Receives Approval
    Zacks2 days ago

    Cancer Treatment Update: Second Gene Therapy Receives Approval

    The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.

  • AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
    Zacks4 days ago

    AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

    AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

  • Reuters4 days ago

    China biotech's 'coming out party' masks long road ahead

    LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (HCM.L), Beigene (BGNE.O) and Zai Lab (ZLAB.O) have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (AZN.L).

  • Reuters - UK Focus4 days ago

    China biotech's 'coming out party' masks long road ahead

    LONDON/SHANGHAI, Oct (Shenzhen: 000069.SZ - news) 19 (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares (Berlin: DI6.BE - news) in firms such as Chi-Med, Beigene and Zai Lab have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (NYSE: AZN - news) .

  • Market Realist5 days ago

    What AstraZeneca’s 3Q17 Performance Tells Us

    AZN stock rose ~0.9% in 3Q17 and has risen ~26.9% YTD (year-to-date) as of October 16.

  • Reuters - UK Focus5 days ago

    Astra and Merck win speedy review for Lynparza in breast cancer

    U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during ...

  • Reuters - UK Focus6 days ago

    Chi-Med, AstraZeneca lung cancer drug shrinks resistant tumours

    LONDON, Oct (Shenzhen: 000069.SZ - news) 17 (Reuters) - An experimental cancer drug discovered by Hutchison China MediTech has demonstrated promising activity in shrinking tumours in lung cancer patients whose disease had worsened following treatment with approved medicines. The treatment, which Hutchison China MediTech or "Chi-Med" is developing with AstraZeneca (NYSE: AZN - news) , is one of a new wave of innovative medicines coming out of Chinese research labs as the country flexes its muscles in drug discovery. Results from small-scale studies presented on Tuesday at a medical meeting in Japan showed that adding savolitinib to either AstraZeneca's Tagrisso or Iressa improved responses.

  • Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
    Zacks7 days ago

    Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

    Foreign markets remain undeterred by discouraging events, notching up weekly gains.

  • Pharma and medtech industries prepare for hard Brexit
    Reuters7 days ago

    Pharma and medtech industries prepare for hard Brexit

    Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc. MeddiQuest, an eight-person consultancy specialising in medical technology regulations, is in the process of moving from outside Cambridge to Ireland. "A significant part of our business is being an authorised EU representative," Chief Executive Neil Armstrong told Reuters.

  • Reuters - UK Focus7 days ago

    Pharma and medtech industries prepare for hard Brexit

    LONDON, Oct (Shenzhen: 000069.SZ - news) 16 (Reuters) - Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc. MeddiQuest, an eight-person consultancy specialising in medical technology regulations, is in the process of moving from outside Cambridge to Ireland (Other OTC: IRLD - news) .

  • Bloomberg7 days ago

    Drug Companies Fear Brexit Will Hit Medicine Trade

    Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.

  • Cancer Space Update: Lung & Breast Cancer Studies in Focus
    Zacks10 days ago

    Cancer Space Update: Lung & Breast Cancer Studies in Focus

    While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

  • Reuters - UK Focus13 days ago

    Pfizer weighs $15 bln sale of consumer healthcare business

    Oct (Shenzhen: 000069.SZ - news) 10 (Reuters) - Pfizer (NYSE: PFE - news) said on Tuesday it was considering the sale or spin-off of its consumer healthcare business, shaking up the industry and potentially putting a headache pill to lip balm operation worth some $15 billion up for grabs. The move comes as Germany's Merck KGaA (LSE: 0O14.L - news) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years.

  • Pfizer weighs $15 bln sale of consumer healthcare business
    Reuters13 days ago

    Pfizer weighs $15 bln sale of consumer healthcare business

    The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.

  • AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
    Zacks14 days ago

    AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

    AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

  • Reuters17 days ago

    FTSE at two-month peak as sterling falters

    British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning groups such as pharma stocks. The FTSE 100 index (.FTSE) closed 0.2 percent up at 7,522.87 points, with Britain's pound on track for its worst week in a year as the Prime Minister hit back at a plot to topple her, saying she would provide "calm leadership" to the country. "The talk of a leadership plot against the Prime Minister is eroding the pound's value and propping up the FTSE 100," CMC Markets analyst David Madden wrote in a note to clients.

  • Reuters - UK Focus17 days ago

    Britain's FTSE at two-month peak as sterling falters

    British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning ...

  • Reuters - UK Focus17 days ago

    Britain's FTSE scales 2-month peak

    The UK's top share index advanced on Friday, holding at its highest level in two months as a weaker pound boosted dollar-earning constituents such as consumer firms and pharma stocks. A dip in the pound ...

  • Drug industry gives up legal battle over new UK cost curbs
    Reuters18 days ago

    Drug industry gives up legal battle over new UK cost curbs

    Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.

  • Reuters - UK Focus18 days ago

    Drug industry gives up legal battle over new UK cost curbs

    LONDON, Oct (Shenzhen: 000069.SZ - news) 5 (Reuters) - Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.

  • Reuters - UK Focus19 days ago

    Drug industry fails to win judicial review of new UK cost curbs

    LONDON, Oct (Shenzhen: 000069.SZ - news) 4 (Reuters) - Britain's pharmaceuticals industry failed to secure a judicial review of new cost curbs, which mean drugs costing NHS England more than 20 million pounds ($26 mln) annually no longer get automatic funding. The Association of the British Pharmaceutical Industry (ABPI) had sought to challenge the additional hurdle to drug uptake that was implemented by the National Institute for Health and Care Excellence (NICE (Other OTC: NCSYF - news) ) earlier this year. On Wednesday it said it was disappointed the judicial review application had been turned down.

  • Tell us how Brexit will work, British companies demand
    Reuters21 days ago

    Tell us how Brexit will work, British companies demand

    British companies including pharmaceuticals giant AstraZeneca urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.

  • Reuters - UK Focus21 days ago

    Tell us how Brexit will work, British companies demand

    MANCHESTER, England, Oct (Shenzhen: 000069.SZ - news) 2 (Reuters) - British companies including pharmaceuticals giant AstraZeneca (NYSE: AZN - news) urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes